UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Terminated
Unique ID issued by UMIN UMIN000029763
Receipt No. R000033810
Scientific Title Phase II study of Osimertinib Treatment on EGFR T790M Cytology Positive NSCLC Patients (DETECTIVE study)
Date of disclosure of the study information 2017/10/30
Last modified on 2019/06/03

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase II study of Osimertinib Treatment on EGFR T790M Cytology Positive NSCLC Patients (DETECTIVE study)
Acronym Phase II study of Osimertinib Treatment on EGFR T790M Cytology Positive NSCLC Patients (DETECTIVE study)
Scientific Title Phase II study of Osimertinib Treatment on EGFR T790M Cytology Positive NSCLC Patients (DETECTIVE study)
Scientific Title:Acronym Phase II study of Osimertinib Treatment on EGFR T790M Cytology Positive NSCLC Patients (DETECTIVE study)
Region
Japan

Condition
Condition EGFR mutation-positive non-small cell lung cancer
Classification by specialty
Pneumology
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 To assess safety and efficacy of osimertinib treatment on EGFR T790M cytology positive non-small cell lung cancer patients who acquired resistance to EGFR tyrosine kinase inhibitors
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes overall response rate: from first administration to last administration
Key secondary outcomes 1) disease control rate
2) progression-free survival
3) safety (adverse event)

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Continue to administer osimertinib to a patient until the patient correspond to the withdrawal criteria
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1) Non-small cell lung cancer (except for squamous cell carcinoma) diagnosed histologically or cytologically
2) Patients with EGFR mutation (Exon 19 deletion or Exon21 L858R) positive, who were received treatment by EGFR tyrosine kinase inhibitors
3) Patients with clinical stages IIIB, IIIC or IV or postoperative recurrence which are confirmed with diagnostic radiology
4) EGFR T790M positive cytology positive
5) Enrollment after 12 weeks from radiation therapy including lung area and after 1 week from radiation therapy not including lung area
6) Age: more than 20 years old at the date or informed consent
7) Eastern Cooperative Oncology Group Performance Status (ECOG PS) is 0 or 1
8) Patients who have measurable lesion designated by RECIST version 1.1
9) Patients with adequate organ function
10) Enrollment after 21 days from the starting date of last cytotoxic anticancer agents or after 4 days from the last dose of EGFR tyrosine kinase inhibitors
11) Patients expected to survive for more than 12 weeks
12) After the details of the trial are explained sufficiently before enrollment in this trial, written consent by patients themselves should be obtained
Key exclusion criteria 1) Treatment history of osimertinib or other third-generation EGFR tyrosine kinase inhibitors (ex. ASP8273)
2) Patients who received other EGFR-tyrosine kinase inhibitors again after disease progression
3) Treatment history of immune checkpoint inhibitors
4) QTc >470 msec
5) Patients with interstitial pneumonia, pulmonary fibrosis or radiation pneumonitis on chest CT
6) Patients with history of drug-related interstitial lung disease
7) Patients with history of serious drug allergy
8) Patients with serious infection or other serious concomitant disease (ex. gastrointestinal bleeding)
9) Uncontrollable pleural effusion, ascites or pericardial effusion
10) Clinically problematic heart disease
11) Uncontrollable diabetes
12) Central nervous system metastasis with a clinical manifestation
13) Patients with active double cancer
14) Clinically problematic psychiatric disorders
15) Unhealed fracture or heavy wound
16) Pregnant or breast-feeding female patients, female patients who have a possibility of pregnancy and does not intend to use birth control till after 6 weeks after last administration or male patients who does not intend to use birth control till after 4 months after last administration
17) Patients judged to be ineligible for safe implementation of this trial by the investigators
Target sample size 58

Research contact person
Name of lead principal investigator
1st name Nobuyuki
Middle name
Last name Katakami
Organization Kobe City Medical Center General Hospital
Division name Department of medical oncology
Zip code 6500047
Address 2-2-1, Minatojimaminamimachi, Chuo-ku, Kobe-city, Hyogo, 650-0047
TEL 078-302-4321
Email katakami@fbri.org

Public contact
Name of contact person
1st name Tatsushi
Middle name
Last name Goto
Organization Secretariat of clinical trial coordinating committee
Division name none
Zip code 5300044
Address Urban Ace Higashitenma-BLDG, 1-1-19, Higashitenma, Kita-ku, Osaka, 530-0044 Japan
TEL 06-6358-7110
Homepage URL
Email gotou@fiverings.co.jp

Sponsor
Institute Kobe City Medical Center General Hospital
Department of medical oncology
Institute
Department

Funding Source
Organization AstraZeneca K.K.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization -
Address -
Tel -
Email -

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 独立行政法人国立病院機構 北海道がんセンター(北海道)、一般財団法人厚生会 仙台厚生病院(宮城県)、愛知県がんセンター中央病院(愛知県)、社会福祉法人京都社会事業財団 京都桂病院(京都府)、関西医科大学附属病院(大阪府)、独立行政法人国立病院機構 刀根山病院(大阪府)、大阪市立総合医療センター(大阪府)、神戸大学医学部附属病院(兵庫県)、地方独立行政法人大阪府立病院機構 大阪国際がんセンター(大阪府)、地方独立行政法人神戸市民病院機構 神戸市立医療センター中央市民病院(兵庫県)、兵庫県立がんセンター(兵庫県)、独立行政法人国立病院機構 四国がんセンター(愛媛県)

Other administrative information
Date of disclosure of the study information
2017 Year 10 Month 30 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled 6
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Terminated
Date of protocol fixation
2017 Year 09 Month 22 Day
Date of IRB
2017 Year 10 Month 11 Day
Anticipated trial start date
2017 Year 12 Month 01 Day
Last follow-up date
2018 Year 11 Month 26 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 10 Month 30 Day
Last modified on
2019 Year 06 Month 03 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033810

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.